REGN Maintained at Outperform by Wolfe Research, May 2026

Wolfe Research maintained its Outperform rating on Regeneron Pharmaceuticals (REGN) on May 18, 2026, though the analyst firm lowered its price target to $860 from $900. This adjustment reflects a more cautious near-term outlook for the biotech giant, which trades at $629.36 with a market cap of $64.8 billion. The Wolfe Research REGN rating change signals confidence in long-term fundamentals while acknowledging current market headwinds. We examine what this means for investors tracking the pharmaceutical sector.

Wolfe Research Maintains Outperform, Cuts Price Target

Wolfe Research kept its Outperform rating intact but reduced the price target by $40 per share to $860. This move reflects a recalibration of near-term expectations for Regeneron’s core franchises. The analyst firm’s decision to hold the rating while trimming upside suggests confidence in REGN’s long-term competitive position despite near-term pressures.

REGN stock has declined 9.87% in one day and trades below its 50-day average of $742.36 and 200-day average of $691.41. The stock’s PE ratio of 15.35 and Meyka AI grade of B+ indicate reasonable valuation relative to growth prospects. Analyst consensus remains bullish with 39 Buy ratings, 8 Hold ratings, and 1 Sell rating among tracked firms.

Financial Metrics Show Solid Fundamentals

Regeneron’s financial profile demonstrates operational strength despite recent price weakness. The company reports EPS of $40.99, free cash flow per share of $39.95, and a debt-to-equity ratio of 0.086, indicating conservative leverage. Operating margins stand at 24.3% with a current ratio of 3.57, reflecting strong liquidity and operational efficiency.

Meyka AI rates REGN with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. The company’s return on equity of 14.3% and operating cash flow of $48.20 per share underscore consistent cash generation supporting its dividend and R&D investments.

Analyst Consensus and Market Outlook

The broader analyst community remains supportive of Regeneron despite Wolfe’s price target reduction. Wolfe Research lowered its price target to $860 from $900, citing near-term headwinds in key therapeutic areas. The consensus rating of 3.0 (Buy) reflects strong backing from the investment community overall.

REGN’s five-year revenue growth per share of 73.6% and free cash flow growth of 11.3% demonstrate consistent value creation. The company’s $64.8 billion market cap positions it as a healthcare sector leader. Earnings are scheduled for announcement on July 30, 2026, which may provide clarity on management’s outlook and pipeline progress.

Technical Setup and Price Forecast

Technical indicators show mixed signals with RSI at 39.29, suggesting oversold conditions. The stock trades near its Bollinger Band lower band of $680.89, indicating potential support. The ADX of 31.78 confirms a strong downtrend currently in place.

Meyka AI forecasts REGN reaching $875.98 within one year and $1,057.80 within five years, implying significant upside from current levels. The year-high of $821.11 and year-low of $476.49 frame the stock’s recent trading range. Volume of 2.99 million shares traded recently exceeds the average of 685,260, indicating active institutional participation during the selloff.

Final Thoughts

Wolfe Research’s maintained Outperform rating on Regeneron reflects confidence in the company’s long-term franchise strength, though the $40 price target reduction acknowledges near-term challenges. REGN’s solid financial metrics, strong cash generation, and analyst consensus support suggest the recent selloff may present opportunity for long-term investors. With earnings due in July and a B+ Meyka grade, the biotech leader remains a core holding for growth-oriented portfolios despite current volatility.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.